Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point 18F-FDG PET/CT Imaging in Patients with Advanced Melanoma-Reference-Cited by-同舟云学术

Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point 18F-FDG PET/CT Imaging in Patients with Advanced Melanoma

Published:2017-03-30 Issue:9 Volume:58 Page:1421-1428
ISSN:0161-5505
Container-title:Journal of Nuclear Medicine
language:en
Short-container-title:J Nucl Med

Author:

Cho Steve Y.,Lipson Evan J.,Im Hyung-Jun,Rowe Steven P.,Gonzalez Esther Mena,Blackford Amanda,Chirindel Alin,Pardoll Drew M.,Topalian Suzanne L.,Wahl Richard L.

Publisher

Society of Nuclear Medicine

Subject

Radiology, Nuclear Medicine and imaging

Reference35 articles.

1. Antagonists of PD-1 and PD-L1 in Cancer Treatment

2. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

3. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

4. Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody

5. Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial [abstract];Hodi;J Clin Oncol.,2014

Cited by 213 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 18F-FDG-PET/CT Uptake by Noncancerous Lung as a Predictor of Interstitial Lung Disease Induced by Immune Checkpoint Inhibitors;Academic Radiology;2024-09

2. PD-1 blockade plus COX inhibitors in dMMR metastatic colorectal cancer: Clinical, genomic, and immunologic analyses from the PCOX trial;Med;2024-08

3. Multimodal Imaging Approach for Tumor Treatment Response Evaluation in the Era of Immunotherapy;Investigative Radiology;2024-07-17

4. [18F]FDG-PET/CT atypical response patterns to immunotherapy in non-small cell lung cancer patients: long term prognosis assessment and clinical management proposal;European Journal of Nuclear Medicine and Molecular Imaging;2024-06-19

5. Is 18F-FDG-PET/CT an Optimal Imaging Modality for Detecting Immune-Related Adverse Events after Immune-Checkpoint Inhibitor Therapy? Pros and Cons;Cancers;2024-05-24